Successful treatment of a child with MEK inhibitor-induced acneiform eruption with low-dose isotretinoin
© 2022 Wiley Periodicals LLC..
Selumetinib is a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off-label for low-grade gliomas. Acneiform eruptions are a known complication of MEKi use, and in some cases, may lead to paused, dose-reduced, or discontinued therapy. Isotretinoin has been reported as an effective treatment for acneiform eruptions secondary to targeted therapies, primarily in the adult population. Here we describe a pediatric patient with a severe acneiform eruption secondary to selumetinib who was successfully treated with low-dose isotretinoin when unresponsive to conventional therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Pediatric dermatology - 39(2022), 4 vom: 27. Juli, Seite 646-647 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gupta, Rohit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acneiform |
|---|
| Anmerkungen: |
Date Completed 26.08.2022 Date Revised 29.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/pde.14959 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344159353 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344159353 | ||
| 003 | DE-627 | ||
| 005 | 20231226022124.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/pde.14959 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344159353 | ||
| 035 | |a (NLM)35896172 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gupta, Rohit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful treatment of a child with MEK inhibitor-induced acneiform eruption with low-dose isotretinoin |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.08.2022 | ||
| 500 | |a Date Revised 29.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a Selumetinib is a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off-label for low-grade gliomas. Acneiform eruptions are a known complication of MEKi use, and in some cases, may lead to paused, dose-reduced, or discontinued therapy. Isotretinoin has been reported as an effective treatment for acneiform eruptions secondary to targeted therapies, primarily in the adult population. Here we describe a pediatric patient with a severe acneiform eruption secondary to selumetinib who was successfully treated with low-dose isotretinoin when unresponsive to conventional therapies | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acneiform | |
| 650 | 4 | |a isotretinoin | |
| 650 | 4 | |a selumetinib | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Mitogen-Activated Protein Kinase Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.12.2 |2 NLM | |
| 650 | 7 | |a Isotretinoin |2 NLM | |
| 650 | 7 | |a EH28UP18IF |2 NLM | |
| 700 | 1 | |a Craddock, Megan F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric dermatology |d 1986 |g 39(2022), 4 vom: 27. Juli, Seite 646-647 |w (DE-627)NLM012965154 |x 1525-1470 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:4 |g day:27 |g month:07 |g pages:646-647 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/pde.14959 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 4 |b 27 |c 07 |h 646-647 | ||